Article and Video CATEGORIES
I have lived with lung cancer since 2005. On this "Giving Tuesday," I ask that you join me in making an end-of-year donation to an organization that truly deserves it, the Global Resource for Advancing Cancer Education (GRACE).
GRACE has had a great year of growth. It conducted three in-person patient forums this year: the ALK+ Patient Forum, the Acquired Resistance in Lung Cancer Patient Forum, and the Immunotherapy for the Treatment of Melanoma, Lung, and Kidney Cancers. I attended two of them and I can tell you that they were amazing. They gave the attendees face-to-face access to experts and the knowledge that real work is being done to help us survive our respective diseases.
GRACE produced and posted over 120 videos on its website in 2014. The topics covered head and neck cancer, kidney cancer, lung cancer and melanoma. On top of that, they posted over 50 updates on the news blogs and fielded 700 questions and inquiries in the online forums.
GRACE intends to hold four more forums in 2015, and to continue educating patients not just in lung cancer, but in a growing number of other cancers where exciting changes are coming.
All of these efforts cost money. I think we’ll only continue to see bigger and better things from GRACE in 2015, but they could surely use your help. Please help GRACE with a generous donation today. By learning as much as we can as patients, we are able to become true participants in our own care. GRACE makes that possible.
[powerpress image="http://cancergrace.org/lung/files/2014/11/LCAM-Nov-2014-Linnea-Duff-App…"]
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…